The estimated Net Worth of Brian Levy is at least 91.5 千$ dollars as of 30 October 2013. Brian Levy owns over 6,000 units of Aerie Pharmaceuticals Inc stock worth over 91,500$ and over the last 11 years Brian sold AERI stock worth over 0$.
Brian has made over 1 trades of the Aerie Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Brian bought 6,000 units of AERI stock worth 60,000$ on 30 October 2013.
The largest trade Brian's ever made was buying 6,000 units of Aerie Pharmaceuticals Inc stock on 30 October 2013 worth over 60,000$. On average, Brian trades about 2,000 units every 0 days since 2013. As of 30 October 2013 Brian still owns at least 6,000 units of Aerie Pharmaceuticals Inc stock.
You can see the complete history of Brian Levy stock trades at the bottom of the page.
Brian's mailing address filed with the SEC is C/O AERIE PHARMACEUTICALS, INC., 135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER, NJ, 07921.
Over the last 11 years, insiders at Aerie Pharmaceuticals Inc have traded over 194,685,628$ worth of Aerie Pharmaceuticals Inc stock and bought 2,240,245 units worth 39,233,665$ . The most active insiders traders include Group Holdings (Sbs) Adviso...、Anand Mehra、Capital Management Ii, Llc .... On average, Aerie Pharmaceuticals Inc executives and independent directors trade stock every 45 days with the average trade being worth of 2,718,618$. The most recent stock trade was executed by Casey C. Kopczynski on 15 February 2021, trading 60,651 units of AERI stock currently worth 12,130$.
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Aerie Pharmaceuticals Inc executives and other stock owners filed with the SEC include: